Anika Therapeutics (ANIK) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.21 -0.93%
Revenue Growth %: +5.9%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
KELYA, ROX, KEEL, More
Revenue Growth %: +5.9%
Financial Fact:
Licensing, milestone and contract revenue: 6K
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.46, $0.01 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $27.2 million versus the consensus estimate of $28.92 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- Kelly Services (KELYA) Misses Q3 EPS by 5c
- Icahn Enterprises L.P. (INGR) Tops Q3 EPS by 12c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
